- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
Détention brevets de la classe A61K 31/475
Brevets de cette classe: 905
Historique des publications depuis 10 ans
|
75
|
89
|
76
|
77
|
57
|
92
|
80
|
91
|
46
|
45
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Purdue Research Foundation | 3676 |
36 |
| Pharmacyclics LLC | 241 |
15 |
| Ipsen Biopharm Limited | 269 |
10 |
| The Regents of the University of California | 20137 |
9 |
| Pfizer Inc. | 3391 |
9 |
| Emory University | 1641 |
9 |
| Oryzon Genomics S.A. | 109 |
8 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2882 |
8 |
| Bristol-myers Squibb Company | 4850 |
7 |
| University of Florida Research Foundation, Inc. | 4052 |
7 |
| CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | 193 |
7 |
| Daiichi Sankyo Company, Limited | 1875 |
7 |
| Les Laboratoires Servier | 536 |
7 |
| Pierre Fabre Medicament | 571 |
7 |
| TopoTarget UK Limited | 15 |
7 |
| Crititech, Inc. | 73 |
6 |
| Epizyme, Inc. | 374 |
6 |
| Ionis Pharmaceuticals, Inc. | 890 |
6 |
| Janssen Biotech, Inc. | 1563 |
6 |
| Vernalis (R&D) Limited | 133 |
6 |
| Autres propriétaires | 722 |